Brivaracetam Impurity A is an impurity that can form during the synthesis, storage, or handling of Brivaracetam, an anticonvulsant drug used for epilepsy management.

Regulatory agencies like the FDA and EMA require monitoring of impurities like Brivaracetam Impurity A to ensure the safety and efficacy of Brivaracetam formulations.

It forms as a by-product during synthesis or under storage conditions involving heat, moisture, or pH changes.

By controlling storage conditions, maintaining optimal pH, and conducting routine quality checks, formation of this impurity can be managed effectively.

Detection methods include GC-MS, LC-MS, and HPLC-MS for accurate profiling and analysis of Brivaracetam Impurity A.

Chemicea provides COA, H-NMR, MASS, HPLC, and TGA reports as standard, with additional reports like CNMR, IR, UV, DEPT, Water content, and CHNS available upon request.

Yes, Chemicea’s documentation meets the standards required by major regulatory agencies including USFDA, EMA, ANVISA, TGA, and PMDA.

It is stable for shipping at room temperature. Specific storage conditions are outlined in the Certificate of Analysis (COA).

Yes, Chemicea offers both standard and customized pack sizes to meet specific client needs.

Chemicea supplies Brivaracetam Impurity A as a reference standard, supporting regulatory compliance, method validation, and impurity analysis for Brivaracetam formulations.